MedTrace Logo

Use of a Hypercaloric and Hyperprotein Supplement Enriched with Immunonutrients in Multi-pathological Malnourished Patients to Improve the Incidence and Prevalence of Pressure Sores

NCT06726486 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2024-12-10

No results posted yet for this study

Summary

The goal of this study is to evaluate the efficacy of a hypercaloric, hyperproteic enteral formula enriched with immunonutrients in preventing and treating pressure injuries in hospitalized malnourished patients.

Participants will take enteral formula (a complete hyperproteic and hypercaloric oral nutritional supplement with a fibre mixture enriched in omega 3, L-arginine and nucleotides, providing vitamin C and Zinc) or a hyperproteic and hypercaloric oral nutritional supplement with fibre mixture every day for 30 days.

Conditions

  • Multimorbidity
  • Comorbidity
  • Malnutrition
  • Pressure Ulcer Prevention

Interventions

DIETARY_SUPPLEMENT

Atémpero

A complete hyperproteic and hypercaloric diet with a mixture of fibres enriched in omega 3, L-arginine and nucleotides (which provides vitamin C and Zinc) was administered.

DIETARY_SUPPLEMENT

Control (Standard treatment)

A complete high-protein and high-calorie diet with mixed fibre was administered.

Sponsors & Collaborators

  • Vegenat Healthcare

    collaborator UNKNOWN

  • Instituto de investigación e innovación biomédica de Cádiz

    collaborator OTHER

  • University of Cadiz

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2023-04-30
Completion
2023-04-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06726486 on ClinicalTrials.gov